Guardant Health (NASDAQ:GH) and Biocept (NASDAQ:BIOC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Valuation and Earnings

This table compares Guardant Health and Biocept’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Guardant Health N/A N/A N/A N/A N/A
Biocept $5.07 million 0.86 -$21.61 million ($23.72) -0.08

Guardant Health has higher earnings, but lower revenue than Biocept.

Institutional & Insider Ownership

10.5% of Biocept shares are held by institutional investors. 2.6% of Biocept shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Guardant Health and Biocept, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Guardant Health 0 1 4 0 2.80
Biocept 0 1 1 0 2.50

Guardant Health presently has a consensus target price of $39.50, suggesting a potential downside of 1.23%. Biocept has a consensus target price of $1.00, suggesting a potential downside of 47.92%. Given Guardant Health’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Guardant Health is more favorable than Biocept.


This table compares Guardant Health and Biocept’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Guardant Health N/A N/A N/A
Biocept -715.42% -456.20% -215.56%


Guardant Health beats Biocept on 6 of the 9 factors compared between the two stocks.

Guardant Health Company Profile

Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.

Biocept Company Profile

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with's FREE daily email newsletter.